A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo

Nature Biotechnology

Volumn 18, Issue 11, 2000, Pages 1197-1202

  Shanafelt, Armen B ^a,b   Lin, Yue ^a,c   Shanafelt, Marie Claude ^a   Forte, Carla P ^a   Dubois Stringfellow, Nathalie ^a   Carter, Christopher ^a   Gibbons, Jacqueline A ^a   Cheng, Shu Lan ^a   Delaria, Katherine A ^a   Fleischer, Richard ^a   Greve, Jeffrey M ^a   Gundel, Robert ^a,d   Harris, Kathleen ^a   Kelly, Ruth ^a   Koh, Beth ^a   Li, Ying ^a   Lantz, Lori ^a   Mak, Polly ^a   Neyer, Lauri ^a   Plym, Mary Jane ^a   Roczniak, Steve ^a   Serban, Daniel ^a   Thrift, John ^a   Tsuchiyama, Linda ^a   Wetzel, Monte ^a   Wong, Mel ^a   Zolotorev, Alya ^a   more..

^a BAYER CORPORATION   (United States)

^b Roche Diagnostics Corporation   (United States)

^c FIBROGEN INC   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cancer; Mutagenesis; Pharmacology; Receptor; Structure function analysis

Indexed keywords

BAY 50 4798; INTERLEUKIN 2 DERIVATIVE; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CHIMPANZEE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; LUNG METASTASIS; MALE; METASTASIS INHIBITION; MONONUCLEAR CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE ACTIVATION; TUMOR MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL SEPARATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-2; KIDNEY; KILLER CELLS, NATURAL; KINETICS; LEUKOCYTES, MONONUCLEAR; LIVER; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION; NEOPLASM TRANSPLANTATION; PAN TROGLODYTES; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TEMPERATURE; TIME FACTORS;

ANIMALIA; PAN (APE); PAN TROGLODYTES; RNA VIRUSES;

EID: 0033758065     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/81199     Document Type: Article

References (38)

1. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
2. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
3. Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease
4. A phase I study of interleukin-2 in children with cancer and evaluation of clinical and immunologic status during therapy. A Pediatric Oncology Group Study
5. Recombinant interleukin-2 in metastatic renal cell carcinoma - A European multicentre phase II study
6. Flavone-8-acetic acid augments systemic natural killer cell activity and synergizss with IL-2 for treatment of murine renal cancer
7. Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion
8. Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer
9. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: Clinical results and immunological effects
10. Lowest dose interleukin-2 immunotherapy
11. The IL-2 receptor beta chain (p70): Role in mediating signals for LAK, NK, and proliferative activities
12. Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: Association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R
13. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: Prolonged immunomodulation without significant toxicity
14. The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2
15. Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma
16. Rational interleukin 2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity
17. Unraveling the structure of IL-2
18. Unraveling the structure of interleukin-2: Reply
19. Interleukin 2 and its receptors: Recent advances and new immunological functions
20. Regulation of IL-2 receptor subunit genes in human monocytes. Differential effects of IL-2 and IFN-gamma
21. Identification of specific residues of human interleukin 2 that affect binding to the 70-kDa subunit (p70) of the interleukin 2 receptor
22. Structural and biologic properties of a human aspartic acid-126 interleukin-2 analog
23. Biological and receptor-binding activities of human interleukin-2 mutated at residues 20Asp, 125Cys or 127Ser
24. Analysis of human IL-2/IL-2 receptor beta chain interactions: Monoclonal antibody H2-8 and new IL-2 mutants define the critical role of alpha helix-A of IL-2
25. Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor
26. Interleukin 2 receptors
27. CD56bright natural killer cell subsets: Characterization of distinct functional responses to interleukin-2 and the c-kit ligand
28. + natural killer cells after in vivo IL-2 therapy: p70 Expression does not alone predict the level of intermediate affinity IL-2 binding
29. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells
30. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2
31. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases
32. Interleukin-2 and cancer therapy
33. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
34. Rapid and efficient site-specific mutagenesis without phenotypic selection
35. CLAMP: A biosensor kinetic data analysis program
36. Structure-activity relationships of recombinant human interleukin 2
37. Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor